Takeda Mikiko Y, Katzman Joanna G, Dole Ernest, Bennett Melissa Heinz, Alchbli Amal, Duhigg Daniel, Yonas Howard
a Department of Pharmacy Practice and Administrative Sciences , University of New Mexico College of Pharmacy , Albuquerque , New Mexico , USA.
b University of New Mexico Pain Center , Albuquerque , New Mexico , USA.
Subst Abus. 2016 Oct-Dec;37(4):591-596. doi: 10.1080/08897077.2016.1179704. Epub 2016 Apr 19.
The epidemic of lethal prescription opioid overdose is one of the most pressing public health problems in the United States. In an ambulatory clinic setting, current practice guidelines suggest that health care providers should screen patient's aberrant drug-related behaviors. Given the difficulty of predicting which patients on chronic opioid therapy (COT) will experience opioid overdose, a new paradigm of harm reduction is called for. In previous studies, naloxone, an opioid antagonist, was given only to high-risk patients. However, if naloxone is co-prescribed in a Universal Precautions manner for all patients receiving COT, this may have a significant impact on intentional and unintentional opioid overdose deaths.
Adult patients treated with COT for chronic noncancer pain are eligible study participants at the University of New Mexico Pain Center. The primary goal of this 1-year study was to develop an efficient Universal Precautions model for co-prescribing of naloxone with COT in the ambulatory clinic setting. Outcome measures included demographic data, detailed medical and substance use history, current morphine equivalent dose (MED), other "high-risk" medications used, and opioid misuse risk.
One hundred and sixty-four patients were enrolled in this study. All subjects were educated about the risks of opioid overdose and provided naloxone rescue kits. No overdoses occurred in the study population. Follow-up data illustrated that approximately 57% of the cohort had depressive disorder, the median MED was 90 mg/day, and the median Current Opioid Misuse Measure score (COMM) was 5.0.
The ambulatory co-prescribing of naloxone in a Universal Precautions model for all patients prescribed COT can be adopted as a useful public health intervention. This study illustrates a model that can be used to educate patients, caregivers, and an interdisciplinary team of health care professionals in an academic medical center.
致命性处方阿片类药物过量流行是美国最紧迫的公共卫生问题之一。在门诊环境中,现行实践指南建议医疗保健提供者应筛查患者异常的药物相关行为。鉴于难以预测哪些接受慢性阿片类药物治疗(COT)的患者会发生阿片类药物过量,需要一种新的减少伤害范式。在先前的研究中,阿片类拮抗剂纳洛酮仅给予高危患者。然而,如果以普遍预防的方式为所有接受COT的患者同时开具纳洛酮,这可能会对有意和无意的阿片类药物过量死亡产生重大影响。
在新墨西哥大学疼痛中心,接受COT治疗慢性非癌性疼痛的成年患者是符合条件的研究参与者。这项为期1年的研究的主要目标是在门诊环境中开发一种高效的普遍预防模型,用于将纳洛酮与COT同时开具。结果指标包括人口统计学数据、详细的医疗和物质使用史、当前吗啡当量剂量(MED)、使用的其他“高危”药物以及阿片类药物滥用风险。
164名患者参加了本研究。所有受试者都接受了阿片类药物过量风险的教育,并获得了纳洛酮急救包。研究人群中未发生过量情况。随访数据表明,该队列中约57%患有抑郁症,MED中位数为90毫克/天,当前阿片类药物滥用测量评分(COMM)中位数为5.0。
为所有开具COT的患者采用普遍预防模式在门诊同时开具纳洛酮可作为一种有用的公共卫生干预措施。本研究展示了一种可用于在学术医疗中心对患者、护理人员和跨学科医疗保健专业团队进行教育的模型。